Abstract 1768
Background
Taste changes can frequently be observed in oncological patients undergoing chemotherapy and are reported as being among the most distressing side effects, along with fatigue, nausea, vomiting, and hair loss. The prevalence of taste changes have been reported in the range of 46%–77%. The aim of this descriptive study was to evaluate taste changes experienced by cancer patients who receive chemotherapy and associated factors with taste changes.
Methods
This is a descriptive a study. The sample of the study consisted of 154 patients who received chemotherapy at Gayrettepe Florence Nightingale Hospital during the period of February 2018 to July 2018. Data were collected by using the patient İnformation form and Chemotherapy-induced Taste Alteration Scale (CiTAS). Mann-Whitney U test, Kruskal-Wallis test, and Spearman Correlation analysis were used to evaluate the data.
Results
The mean age of patients was 57,40±12,748 years, 62.3% of them were women, 43.5% of them were university graduates, 73.4% were married and 70.8% of them were employed in any job. According to CiTAS scores, the most discomfort in taste patients experienced was because of nausea, vomiting, odor disturbance and loss of appetite during the chemotherapy process. According to CiTAS score the least discomfort experienced by patients were tasting basic flavors including the taste of the sweet, salty, bitter flavors and the broth. As a result of the comparison of CiTAS score some sociodemographic and medical characteristics of patients, it was found that women experience more paraguzi and fantoguzi than men. As the age of the patients increased, the problems in taste were decreased. Patients who do not take other drugs than chemotherapy have fewer taste problems.
Conclusions
In conclusion, it is recommended to include changes in taste sensation along with other side effects in the evaluation of treatment-related processes of cancer patients, and to add practices related to management of taste changes in the care plan of the patients by taking into account the factors that may be associated with taste.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5056 - Phase 2 study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
5710 - Avelumab for advanced Merkel cell carcinoma in the Netherlands; a nationwide survey
Presenter: Sonja Levy
Session: Poster Display session 3
Resources:
Abstract
3152 - Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data
Presenter: Sandra D'Angelo
Session: Poster Display session 3
Resources:
Abstract
5715 - A Phase 2, Randomized Study of Nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and Stereotactic Body Radiation Therapy (SBRT) for Metastatic Merkel Cell Carcinoma (MCC, NCT03071406) – a preliminary report.
Presenter: Sungjune Kim
Session: Poster Display session 3
Resources:
Abstract
2854 - Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma
Presenter: Kalijn Bol
Session: Poster Display session 3
Resources:
Abstract
2928 - Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients
Presenter: Mathilde Saint-Ghislain
Session: Poster Display session 3
Resources:
Abstract
1235 - Incidence and survival of Uveal Melanoma occurring as single cancer versus its occurrence as a first or second primary neoplasm
Presenter: Ahmad Alfaar
Session: Poster Display session 3
Resources:
Abstract
3615 - Validation of a Clinicopathological and Gene Expression Profile (CP-GEP) Model for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
Presenter: Evalyn Mulder
Session: Poster Display session 3
Resources:
Abstract
1793 - External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the Surveillance, Epidemiology and End Results (SEER) Program
Presenter: Angelina Tjokrowidjaja
Session: Poster Display session 3
Resources:
Abstract
4278 - Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts).
Presenter: Ines Pires da Silva
Session: Poster Display session 3
Resources:
Abstract